This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally smallmolecules. It’s all well and good to say, “we should drug RNA,” but which RNA? Prior to 2015, I had a casual relationship, at best, with targeting RNA.
Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.
While there was a slight chance that my roommates, with no chemistry knowledge, could have accidentally created the structure of a blockbuster drug, it was highly improbable. Examining molecules produced by LLMs gives me a similar impression. It's like someone with no chemistry background is trying to generate a molecule.
At Sygnature Discovery, we utilise various biophysical technologies to create assays for diverse targets, integral to every stage of the drug discovery process, from hit identification to candidate selection. Covalent drugs may have advantages over non-covalent molecules, such as greater potency and duration of action.
At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities.
Marto SLAS Discovery, 2024 [link] Target-based screening of covalent fragment libraries with mass spectrometry has emerged as a powerful strategy to identify chemical starting points for smallmolecule inhibitors or find new binding pockets on proteins of interest.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content